torcetrapib:
There is some displeasure here as well regarding the 2 in 1 pill that Pfizer is going to be pushing. In fact, the recent lipitor / crestor trial was perceived as disingenous by many, so Pfizer is slowly annoying docs.
But the thing with torcetrapib is that it will be a rather impressive advancement in cholesterol "adjustment". Yes... adjustment. The pfizer reps around here have stopped saying cholesterol "management" but are using the word "adjustment" to slowly try and differentiate torcetrapib from lipitor. I'm not sure that docs will be able to avoid prescribing torcetrapib simply because they're annoyed at pfizer's marketing tactics. C'est la vie.
And blade, there are certainly people such as yourself that don't tolerate lipitor. But from pfizer's marketing perspective (callous as it may be), you're in the minority and not relevant to their marketing plans (not trying to be harsh to you personally!). Individuals such as yourself would never be suitable for torcetrapib to begin with, so Pfizer doesn't see the combination as an inconvenience in this regard.
We'll see how it turns out. Maybe I'll get my cholesterol "adjusted" :-)
Market Data 
Markets 
AI
